injection-istock-507070936_brianajackson-1
6 March 2018Americas

Mylan partners to make Botox biosimilar

Mylan has revealed plans to develop and commercialise a proposed biosimilar to Botox (onabotulinumtoxinA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

More on this story

Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

More on this story

Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.